v3.25.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Preferred Stock
Redeemable Convertible Preferred Shares Series Seed Preferred Shares
Preferred Stock
Redeemable Convertible Preferred Shares Series B Preferred Shares
Preferred Stock
Redeemable Convertible Preferred Shares Series C-1 Preferred Shares
Preferred Stock
Redeemable Convertible Preferred Shares Series C-2 Preferred Shares
Preferred Stock
Total Redeemable Convertible Preferred Shares
Preferred Stock
Series A Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
IKENA ONCOLOGY INC
IKENA ONCOLOGY INC
Series A Non-Voting Convertible Preferred Stock
IKENA ONCOLOGY INC
Common Stock
IKENA ONCOLOGY INC
Additional Paid-in Capital
IKENA ONCOLOGY INC
Accumulated Deficit
IKENA ONCOLOGY INC
Accumulated Other Comprehensive Income (Loss)
Beginning Balance, Shares at Dec. 31, 2022   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 318,469,306           3,021,409      
Beginning Balance at Dec. 31, 2022 $ (94,084) $ 671 $ 24,847 $ 70,452 $ 40,363 $ 136,333 $ 18,967 $ 10   $ (111,444) $ (1,617) $ 146,969   $ 3 $ 361,948 $ (214,219) $ (763)
Issuance of preferred stock in connection with the Acquisition, net of issuance costs                         $ 32,545        
Issuance of preferred stock in connection with the Acquisition, net of issuance costs, Shares                         4,153,439        
Conversion of preferred stock to common stock                         $ (31,886)        
Conversion of preferred stock to common stock, Shares                         (4,153,439)        
Conversion of preferred stock to common stock                       31,887     31,887    
Conversion of preferred stock to common stock, Shares                           346,119      
Issuance of common stock in connection with the Acquisition, net of issuance costs                       14,111     14,111    
Issuance of common stock in connection with the Acquisition, net of issuance costs, Shares                           150,054      
Cash consideration paid to settle Pionyr restricted stock units, stock options, and unaccredited stockholders                       (285)     (285)    
Temporary equity, cash consideration paid to settle Pionyr restricted stock units, stock options, and unaccredited stockholders                         $ (659)        
Issuance of common stock for underwritten registered offering, net of offering costs                       37,421   $ 1 37,420    
Issuance of common stock for underwritten registered offering, net of offering costs, Shares                           509,166      
Repurchase of common stock                       (663)     (663)    
Repurchase of common stock, Shares                           (8,125)      
Issuance of ordinary shares upon exercise of stock options 150               $ 150     136     136    
Issuance of ordinary shares upon exercise of stock options, Shares               3,000,000           2,835      
Accretion of Redeemable Convertible Preferred Shares to redemption value (10,890) $ 114 $ 1,978 $ 5,407 $ 3,391 10,890     (150) (10,740)              
Stock-based compensation expense                       7,632     7,632    
Other comprehensive income (loss)                       715         715
Foreign currency translation adjustment (136)                   (136)            
Net loss (21,148)                 (21,148)   (68,166)       (68,166)  
Ending Balance, Shares at Dec. 31, 2023   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 321,469,306           4,021,458      
Ending Balance at Dec. 31, 2023 (126,108) $ 785 $ 26,825 $ 75,859 $ 43,754 147,223 $ 18,967 $ 10   (143,332) (1,753) 169,757   $ 4 452,186 (282,385) (48)
Issuance of ordinary shares upon exercise of stock options 13,965               13,965                
Accretion of Redeemable Convertible Preferred Shares to redemption value (2,851) $ 31 $ 517 $ 1,414 $ 889 2,851     (2,851)                
Stock-based compensation expense                       2,001     2,001    
Other comprehensive income (loss)                       (265)         (265)
Foreign currency translation adjustment (38)                   (38)            
Net loss (22,314)                 (22,314)   (16,146)       (16,146)  
Ending Balance, Shares at Mar. 31, 2024   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 321,469,306           4,021,458      
Ending Balance at Mar. 31, 2024 (137,346) $ 816 $ 27,342 $ 77,273 $ 44,643 150,074 $ 18,967 $ 10 11,114 (165,646) (1,791) 155,347   $ 4 454,187 (298,531) (313)
Beginning Balance, Shares at Dec. 31, 2023   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 321,469,306           4,021,458      
Beginning Balance at Dec. 31, 2023 (126,108) $ 785 $ 26,825 $ 75,859 $ 43,754 147,223 $ 18,967 $ 10   (143,332) (1,753) $ 169,757   $ 4 452,186 (282,385) (48)
Issuance of ordinary shares upon exercise of stock options, Shares                       0          
Foreign currency translation adjustment (100)                                
Net loss (28,573)                     $ (29,876)          
Ending Balance, Shares at Jun. 30, 2024   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 321,469,306           4,021,458      
Ending Balance at Jun. 30, 2024 (146,575) $ 849 $ 27,869 $ 78,715 $ 45,549 152,982 $ 18,967 $ 10 8,206 (171,905) (1,853) 142,859   $ 4 455,466 (312,261) (350)
Beginning Balance, Shares at Dec. 31, 2023   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 321,469,306           4,021,458      
Beginning Balance at Dec. 31, 2023 (126,108) $ 785 $ 26,825 $ 75,859 $ 43,754 147,223 $ 18,967 $ 10   (143,332) (1,753) $ 169,757   $ 4 452,186 (282,385) (48)
Issuance of ordinary shares upon exercise of stock options $ 13,965             $ 7 13,958                
Issuance of ordinary shares upon exercise of stock options, Shares 0             140,636,592       0          
Accretion of Redeemable Convertible Preferred Shares to redemption value $ (11,816) $ 134 $ 2,141 $ 5,855 $ 3,686 11,816     (11,816)                
Stock-based compensation expense                       $ 5,295     5,295    
Other comprehensive income (loss)                       116         116
Foreign currency translation adjustment (38)                   (38)            
Net loss (36,568)                 (36,568)   (49,234)       (49,234)  
Ending Balance, Shares at Dec. 31, 2024   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 462,105,898           4,021,458      
Ending Balance at Dec. 31, 2024 (160,565) $ 919 $ 28,966 $ 81,714 $ 47,440 159,039 $ 18,967 $ 17 2,142 (179,900) (1,791) 125,934   $ 4 457,481 (331,619) 68
Beginning Balance, Shares at Mar. 31, 2024   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 321,469,306           4,021,458      
Beginning Balance at Mar. 31, 2024 (137,346) $ 816 $ 27,342 $ 77,273 $ 44,643 150,074 $ 18,967 $ 10 11,114 (165,646) (1,791) $ 155,347   $ 4 454,187 (298,531) (313)
Issuance of ordinary shares upon exercise of stock options, Shares                       0          
Accretion of Redeemable Convertible Preferred Shares to redemption value (2,908) $ 33 $ 527 $ 1,442 $ 906 2,908     (2,908)                
Stock-based compensation expense                       $ 1,279     1,279    
Other comprehensive income (loss)                       (37)         (37)
Foreign currency translation adjustment (62)                   (62)            
Net loss (6,259)                 (6,259)   (13,730)       (13,730)  
Ending Balance, Shares at Jun. 30, 2024   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 321,469,306           4,021,458      
Ending Balance at Jun. 30, 2024 (146,575) $ 849 $ 27,869 $ 78,715 $ 45,549 152,982 $ 18,967 $ 10 8,206 (171,905) (1,853) 142,859   $ 4 455,466 (312,261) (350)
Beginning Balance, Shares at Dec. 31, 2024   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 462,105,898           4,021,458      
Beginning Balance at Dec. 31, 2024 (160,565) $ 919 $ 28,966 $ 81,714 $ 47,440 159,039 $ 18,967 $ 17 2,142 (179,900) (1,791) 125,934   $ 4 457,481 (331,619) 68
Issuance of ordinary shares upon exercise of stock options 45               45                
Issuance of ordinary shares upon exercise of stock options, Shares               578,125                  
Accretion of Redeemable Convertible Preferred Shares to redemption value (3,051) $ 36 $ 552 $ 1,510 $ 953 3,051     (2,244) (807)              
Stock-based compensation expense 57               57     904     904    
Other comprehensive income (loss)                       31         31
Foreign currency translation adjustment (9)                   (9)            
Net loss (6,077)                 (6,077)   (8,619)       (8,619)  
Ending Balance, Shares at Mar. 31, 2025   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 462,684,023           4,021,458      
Ending Balance at Mar. 31, 2025 (169,600) $ 955 $ 29,518 $ 83,224 $ 48,393 162,090 $ 18,967 $ 17   (186,784) (1,800) 118,250   $ 4 458,385 (340,238) 99
Beginning Balance, Shares at Dec. 31, 2024   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 462,105,898           4,021,458      
Beginning Balance at Dec. 31, 2024 (160,565) $ 919 $ 28,966 $ 81,714 $ 47,440 159,039 $ 18,967 $ 17 $ 2,142 (179,900) (1,791) $ 125,934   $ 4 457,481 (331,619) 68
Issuance of ordinary shares upon exercise of stock options, Shares                       0          
Foreign currency translation adjustment (26)                                
Net loss (13,662)                     $ (11,386)          
Ending Balance, Shares at Jun. 30, 2025   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 462,684,023           4,021,458      
Ending Balance at Jun. 30, 2025 (180,351) $ 994 $ 30,088 $ 84,780 $ 49,377 165,239 $ 18,967 $ 17   (197,518) (1,817) 115,907   $ 4 458,843 (343,005) 65
Beginning Balance, Shares at Mar. 31, 2025   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 462,684,023           4,021,458      
Beginning Balance at Mar. 31, 2025 (169,600) $ 955 $ 29,518 $ 83,224 $ 48,393 162,090 $ 18,967 $ 17   (186,784) (1,800) $ 118,250   $ 4 458,385 (340,238) 99
Issuance of ordinary shares upon exercise of stock options, Shares                       0          
Accretion of Redeemable Convertible Preferred Shares to redemption value (3,149) $ 39 $ 570 $ 1,556 $ 984 3,149       (3,149)              
Stock-based compensation expense                       $ 458     458    
Other comprehensive income (loss)                       (34)         (34)
Foreign currency translation adjustment (17)                   (17)            
Net loss (7,585)                 (7,585)   (2,767)       (2,767)  
Ending Balance, Shares at Jun. 30, 2025   71,428,571 239,156,361 270,636,854 127,875,914   326,079,495 462,684,023           4,021,458      
Ending Balance at Jun. 30, 2025 $ (180,351) $ 994 $ 30,088 $ 84,780 $ 49,377 $ 165,239 $ 18,967 $ 17   $ (197,518) $ (1,817) $ 115,907   $ 4 $ 458,843 $ (343,005) $ 65